Twelve-month safety of intravitreal injections of bevacizumab (Avastin®): Results of the pan-american collaborative retina study group (PACORES)
DOI 10.1007/s00417-007-0660-z
Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, Arevalo J F, Berrocal MH, Farah ME et al.; Pan American Collaborative Retina Group (PACORES). Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87. (Pubitemid 350167096)
Complications in patients after intravitreal injection of bevacizumab
Schima C, Sakaquchi H, Gomi F, Kamei M, Ikuno Y, Oshima Y, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Ophthalmol. 2008;86:372-376.
Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock)
Limsuwan T, Demoly P. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am 2010;94:691-710.